



**virax**  
Virax Holdings Limited  
ABN 56 006 569 106

**ASX ANNOUNCEMENT**  
**April 1, 2003**

**VIRAX SIGNS SUPPLY AGREEMENT  
WITH LEADING U.S. BIOTECHNOLOGY COMPANY**

Melbourne, Australia – April 1, 2003 – Virax Holdings Ltd (ASX:VHL) today announced that it has entered into a supply agreement with MedImmune, Inc., a leading biotechnology company headquartered in Gaithersburg, Maryland USA. Under the supply agreement, Virax will provide technology to MedImmune for use in the development of potential future products. Virax will receive up to AUD\$400,000 from MedImmune upon the successful delivery of the technology specified in the agreement. No additional details from the agreement were disclosed.

Dr. David Beames, chief executive officer of Virax, said, “Overseas recognition of our expertise is important as we continue to progress Virax technologies and products. It is very gratifying that Virax is gaining this recognition for its accomplishments. Virax hopefully can build on this initial relationship.”

Melbourne-based Virax Holdings Ltd is a publicly listed, development stage biotechnology company engaged in the commercial development of immune-based therapies for HIV/AIDS, cancer, other infectious diseases, and autoimmune diseases. Virax's business strategy is to identify, in-license and take promising early stage biotechnologies through the early stages of clinical development towards the pharmaceutical market.

\*\*\*\*

For further information, please contact:

Dr David Beames  
Chief Executive Officer  
Virax Holdings Ltd  
Phone: (03) 9854 6230  
Email: [virax@virax.com.au](mailto:virax@virax.com.au)

Ms Tracy Hocking  
Corporate Communications Manager  
Virax Holdings Ltd  
Mobile: 0421 061166  
Email: [tracyhocking@optusnet.com.au](mailto:tracyhocking@optusnet.com.au)